Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax~R platform in the treatment of glioblastoma multiforme

摘要

DCVax~R (Northwest Biotherapeutics, Inc., MD, USA) is a platform technology for delivering dendritic cell-based therapeutic vaccines for a variety of cancers, including glioblastoma multiforme (GBM). DCVax~R-L, one of the implementations of the DCVax platform, provides personalized active immunotherapy composed of autologous dendritic cells pulsed with autologous whole tumor lysate. Clinical trials with DCVax-L for GBM included previous Phase l/ll clinical trials and an ongoing Phase III trial. Preliminary reports of patient outcomes after administration of the DCVax-L vaccine provide a promising therapeutic